JP2015515494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515494A5 JP2015515494A5 JP2015509101A JP2015509101A JP2015515494A5 JP 2015515494 A5 JP2015515494 A5 JP 2015515494A5 JP 2015509101 A JP2015509101 A JP 2015509101A JP 2015509101 A JP2015509101 A JP 2015509101A JP 2015515494 A5 JP2015515494 A5 JP 2015515494A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- compound
- pharmaceutical composition
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 150000001875 compounds Chemical class 0.000 claims description 65
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 239000002777 nucleoside Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 17
- 102000014150 Interferons Human genes 0.000 claims description 16
- 108010050904 Interferons Proteins 0.000 claims description 16
- 229940047124 interferons Drugs 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- -1 -SR e Chemical group 0.000 claims description 10
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 10
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 9
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 8
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 8
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229960000329 ribavirin Drugs 0.000 claims description 8
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 8
- 125000003835 nucleoside group Chemical group 0.000 claims description 7
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 0 Cc1c(*)ccc(-c(cc2)cc(CC3)c2-c2c3[n]c(C3N(*)CC(*)C3)n2)c1 Chemical compound Cc1c(*)ccc(-c(cc2)cc(CC3)c2-c2c3[n]c(C3N(*)CC(*)C3)n2)c1 0.000 description 7
- 238000009472 formulation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637956P | 2012-04-25 | 2012-04-25 | |
| US61/637,956 | 2012-04-25 | ||
| US201361773977P | 2013-03-07 | 2013-03-07 | |
| US61/773,977 | 2013-03-07 | ||
| PCT/US2013/037934 WO2013163270A1 (en) | 2012-04-25 | 2013-04-24 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515494A JP2015515494A (ja) | 2015-05-28 |
| JP2015515494A5 true JP2015515494A5 (https=) | 2016-04-21 |
| JP6069492B2 JP6069492B2 (ja) | 2017-02-01 |
Family
ID=48227586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509101A Expired - Fee Related JP6069492B2 (ja) | 2012-04-25 | 2013-04-24 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9066944B2 (https=) |
| EP (1) | EP2850072B1 (https=) |
| JP (1) | JP6069492B2 (https=) |
| CN (1) | CN104302636B (https=) |
| CA (1) | CA2869908C (https=) |
| ES (1) | ES2599665T3 (https=) |
| WO (1) | WO2013163270A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163262A1 (en) * | 2012-04-25 | 2013-10-31 | Theravance, Inc. | Piperazine-piperidine compounds as hepatitis c virus inhibitors |
| GB202013383D0 (en) * | 2020-08-26 | 2020-10-07 | Givaudan Sa | Process |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| HUE030465T2 (hu) | 2009-05-13 | 2017-05-29 | Antivirális vegyületek | |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20130244A1 (es) * | 2010-01-25 | 2013-03-10 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c |
| EP2545060B1 (en) | 2010-03-09 | 2015-11-25 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| SG187183A1 (en) * | 2010-08-04 | 2013-02-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2012021704A1 (en) * | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8921372B2 (en) | 2010-11-04 | 2014-12-30 | Theravance Biopharma R&D Ip, Llc | Inhibitors of hepatitis C virus |
| SG11201401891RA (en) * | 2011-11-03 | 2014-05-29 | Theravance Inc | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
| WO2013165796A1 (en) * | 2012-05-03 | 2013-11-07 | Theravance, Inc. | Crystalline form of a pyridyl-piperazinyl hepatitis c virus inhibitor |
-
2013
- 2013-04-24 EP EP13719696.0A patent/EP2850072B1/en active Active
- 2013-04-24 CA CA2869908A patent/CA2869908C/en not_active Expired - Fee Related
- 2013-04-24 WO PCT/US2013/037934 patent/WO2013163270A1/en not_active Ceased
- 2013-04-24 CN CN201380022245.8A patent/CN104302636B/zh not_active Expired - Fee Related
- 2013-04-24 US US13/869,228 patent/US9066944B2/en not_active Expired - Fee Related
- 2013-04-24 JP JP2015509101A patent/JP6069492B2/ja not_active Expired - Fee Related
- 2013-04-24 ES ES13719696.0T patent/ES2599665T3/es active Active
-
2015
- 2015-05-21 US US14/718,296 patent/US9365549B2/en not_active Expired - Fee Related